Election 2020: What will it mean for R&D?

The 2016 U.S. election had a big, albeit short-lived, effect on biopharma, with Hillary Clinton’s drug pricing tweet sinking stocks and putting a chill on a hot IPO market. This time around, drug pricing is arguably higher up the agenda, setting the stage for another bumpy ride.